Currently Viewing:
SGO Annual Meeting on Women's Cancer
Dr Martha Gaines Discusses the Importance of the Patient Voice
March 25, 2018
Clinical Trials Can Reduce Disparities in Advanced Ovarian Cancer, but Funding Is Needed, Researchers Say
March 25, 2018
Dr Scott Page: Diversity in Healthcare Improves Patient Outcomes
March 25, 2018
Deciding When to Use PARP Inhibitors, and Which One
March 25, 2018
Boys Don't Get HPV Vaccination Because Doctors Don't Recommend It, Study Finds
March 25, 2018
Dr Victoria Bae-Jump on Obesity and Endometrial Cancer
March 25, 2018
Dr Anna Beavis Discusses Gender Differences in HPV Vaccination
March 25, 2018
Putting PARP Inhibitor Perspectives Into Practice in "Beyond the Guidelines" Session
March 26, 2018
Dr Oliver Dorigo on New, Innovative Therapies in Gynecologic Cancers
March 26, 2018
Dr William Cliby Explains Predictors of Patient Outcomes in Ovarian Cancer
March 26, 2018
Study Explores Mechanism Linking Statin to Reduced Tumor Size in Endometrial Cancer
March 26, 2018
Study Models ASCO Alternative Payment Model in Advanced Ovarian Cancer Care
March 27, 2018
Dr Sean C. Dowdy: Reducing Opioid Abuse in Patients Undergoing Surgery for Gynecologic Malignancies
April 04, 2018
Currently Reading
Dr Victoria Bae-Jump Discusses Standard of Care, Novel Therapies For Endometrial Cancer
April 11, 2018
Dr Anna Beavis Highlights Importance of Addressing Gender Gaps in HPV Vaccination
April 15, 2018
Dr William Cliby: Patient Factors and Surgery, Quality of Care For Ovarian Cancer
April 16, 2018
Dr Sean C. Dowdy Discusses Improving Surgical Outcomes in Gynecologic Oncology
April 18, 2018
Dr Martha Gaines: Turning Experience as Cancer Survivor into Patient Advocacy
April 20, 2018
Dr Oliver Dorigo on Identified Biomarkers in Gynecologic Malignancies
April 25, 2018
Dr Victoria Bae-Jump on Challenges in Treating Patients With Endometrial Cancer
April 27, 2018
Dr William Cliby Discusses Improving Surgical Outcomes in Ovarian Cancer
April 30, 2018
Dr Sean C. Dowdy on Delays Between Discovering Improved Treatment, Practice and the Application of It
May 05, 2018
Dr Martha Gaines on Helping Patients Understand Their Disease, Identifying Available Resources
May 11, 2018
Dr Oliver Dorigo Discusses an Interdisciplinary Approach to Care in Gynecologic Oncology
May 14, 2018

Dr Victoria Bae-Jump Discusses Standard of Care, Novel Therapies For Endometrial Cancer

Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center, discusses the current standard of treatment for patients with advanced endometrial cancer as well as the role novel therapies, such as targeted therapies and immunotherapy, play in the treatment of the disease.


Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center, discusses the current standard of treatment for patients with advanced endometrial cancer as well as the role novel therapies, such as targeted therapies and immunotherapy, play in the treatment of the disease.

Transcript

What is the current standard of treatment for patients with advanced endometrial cancer?

Our current standard of care treatment for advanced endometrial cancer would usually be surgery first, if it looks doable by their imaging, meaning it’s confined to the abdomen and pelvis, there’s not distant disease like in the lungs or someplace where we don’t think we can resect it. Then, usually that’s followed by chemotherapy. The 2 drugs that have the greatest efficacy for endometrial cancer right now is paclitaxel and carboplatin, and usually that’s 6 cycles of both treatments. Then, plus or minus radiation, depending on the treating gynecologic oncologist’s preference and sort of risk factors and things in where the cancer was and wasn’t during the surgery.

Do targeted therapies or immunotherapy play a role in the treatment of endometrial cancer? Are there any identified biomarkers to predict response to these therapies?

So, right now there haven’t been any FDA approved treatments for endometrial cancer, which would include targeted therapies, actually since hormonal therapy. So, we really desperately need more research on targeted therapies for endometrial cancer for sure. We are looking at many things, including mTOR inhibitors. We’re looking at antiangiogenic agents.

I think the things we’re most excited about is PD-1 inhibitor therapy with mismatched repair deficient tumors looking like a good biomarker for immunotherapy for endometrial cancer. Also, endometrial cancers have a fair amount of tumors that are mismatched repair deficient. So, I think right now that’s our most exciting biomarker and treatment, and there is FDA approval for PD-1 inhibitors in patients across cancers that have mismatched repair deficient tumors.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up